Plasmid DNA vaccines for veterinary use – Scientific guideline
Submitted by Anonymous (not verified) on 26 January 2024 - 13:21
Plasmid DNA vaccines for veterinary use – Scientific guideline
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2024
Submitted by Anonymous (not verified) on 26 January 2024 - 12:40
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2024
Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines
Submitted by Anonymous (not verified) on 26 January 2024 - 12:18
Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines
Clinical data publication
Submitted by Anonymous (not verified) on 26 January 2024 - 12:00
Clinical data publication
Summary of opinion: Apexxnar, 25/01/2024 Positive
Submitted by Anonymous (not verified) on 26 January 2024 - 11:52
Summary of opinion: Apexxnar, 25/01/2024 Positive
Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive
Submitted by Anonymous (not verified) on 26 January 2024 - 11:49
Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024
Submitted by Anonymous (not verified) on 26 January 2024 - 11:00
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024
Summary of opinion: Abecma, 25/01/2024 Positive
Submitted by Anonymous (not verified) on 26 January 2024 - 11:00
Summary of opinion: Abecma, 25/01/2024 Positive
EMA confirms measures to minimise the risk of serious side effects with medicines containing pseudoephedrine
Submitted by Anonymous (not verified) on 26 January 2024 - 11:00
EMA confirms measures to minimise the risk of serious side effects with medicines containing pseudoephedrine
Clinical evaluation of medicinal products intended for treatment of hepatitis B - Scientific guideline
Submitted by Anonymous (not verified) on 26 January 2024 - 9:00
Clinical evaluation of medicinal products intended for treatment of hepatitis B - Scientific guideline